<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">However, the results from clinical trials might only partially be conferred to patients in routine care as the patient populations can differ considerably, mainly due to the stringent inclusion criteria of randomised clinical trials. In metastatic renal cell carcinoma, for instance, 35â€“57% of the patients in routine care would be deemed ineligible for clinical trials, as assessed by common exclusion criteria [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR16">16</xref>]. Data from prospective, clinical cohort studies like ours are of high importance, as they complement the results from clinical trials and generate data on the tolerability and effectiveness of new therapies in daily practice [
 <xref ref-type="bibr" rid="CR17">17</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
